These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 30422717)
1. FDG PET/MRI Coregistration Helps Predict Response to Gamma Knife Radiosurgery in Patients With Brain Metastases. Leiva-Salinas C; Muttikkal TJE; Flors L; Puig J; Wintermark M; Patrie JT; Rehm PK; Sheehan JP; Schiff D AJR Am J Roentgenol; 2019 Feb; 212(2):425-430. PubMed ID: 30422717 [TBL] [Abstract][Full Text] [Related]
2. Brain metastases after stereotactic radiosurgery using the Leksell gamma knife: can FDG PET help to differentiate radionecrosis from tumour progression? Belohlávek O; Simonová G; Kantorová I; Novotný J; Liscák R Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):96-100. PubMed ID: 12483415 [TBL] [Abstract][Full Text] [Related]
3. Usefulness of semiquantitative FDG-PET in the prediction of brain tumor treatment response to gamma knife radiosurgery. Lee JK; Liu RS; Shiang HR; Pan DH J Comput Assist Tomogr; 2003; 27(4):525-9. PubMed ID: 12886136 [TBL] [Abstract][Full Text] [Related]
4. FDG PET/MR Imaging Coregistration Helps Predict Survival in Patients with Glioblastoma and Radiologic Progression after Standard of Care Treatment. Leiva-Salinas C; Schiff D; Flors L; Patrie JT; Rehm PK Radiology; 2017 May; 283(2):508-514. PubMed ID: 28234553 [TBL] [Abstract][Full Text] [Related]
5. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery--in malignant glioma. Tsuyuguchi N; Takami T; Sunada I; Iwai Y; Yamanaka K; Tanaka K; Nishikawa M; Ohata K; Torii K; Morino M; Nishio A; Hara M Ann Nucl Med; 2004 Jun; 18(4):291-6. PubMed ID: 15359921 [TBL] [Abstract][Full Text] [Related]
6. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? Tsuyuguchi N; Sunada I; Iwai Y; Yamanaka K; Tanaka K; Takami T; Otsuka Y; Sakamoto S; Ohata K; Goto T; Hara M J Neurosurg; 2003 May; 98(5):1056-64. PubMed ID: 12744366 [TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy. Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365 [TBL] [Abstract][Full Text] [Related]
8. Impact of the radiosurgery prescription dose on the local control of small (2 cm or smaller) brain metastases. Mohammadi AM; Schroeder JL; Angelov L; Chao ST; Murphy ES; Yu JS; Neyman G; Jia X; Suh JH; Barnett GH; Vogelbaum MA J Neurosurg; 2017 Mar; 126(3):735-743. PubMed ID: 27231978 [TBL] [Abstract][Full Text] [Related]
9. Usefulness of (18)F-fluorodeoxyglucose PET for radiosurgery planning and response monitoring in patients with recurrent spinal metastasis. Gwak HS; Youn SM; Chang U; Lee DH; Cheon GJ; Rhee CH; Kim K; Kim HJ Minim Invasive Neurosurg; 2006 Jun; 49(3):127-34. PubMed ID: 16921451 [TBL] [Abstract][Full Text] [Related]
10. Fluorodeoxyglucose positron emission tomography response and normal tissue regeneration after stereotactic body radiotherapy to liver metastases. Stinauer MA; Diot Q; Westerly DC; Schefter TE; Kavanagh BD Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e613-8. PubMed ID: 22494588 [TBL] [Abstract][Full Text] [Related]
11. Differentiation between Treatment-Induced Necrosis and Recurrent Tumors in Patients with Metastatic Brain Tumors: Comparison among Tomura N; Kokubun M; Saginoya T; Mizuno Y; Kikuchi Y AJNR Am J Neuroradiol; 2017 Aug; 38(8):1520-1527. PubMed ID: 28619837 [TBL] [Abstract][Full Text] [Related]
12. Although Non-diagnostic Between Necrosis and Recurrence, FDG PET/CT Assists Management of Brain Tumours After Radiosurgery. Torrens M; Malamitsi J; Karaiskos P; Valotassiou V; Laspas F; Andreou J; Stergiou C; Prassopoulos V In Vivo; 2016; 30(4):513-20. PubMed ID: 27381617 [TBL] [Abstract][Full Text] [Related]
13. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value. Satoh Y; Onishi H; Nambu A; Araki T Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640 [TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiation therapy for liver oligometastases: predictive factors of local response by Mazzola R; Fersino S; Alongi P; Di Paola G; Gregucci F; Aiello D; Tebano U; Pasetto S; Ruggieri R; Salgarello M; Alongi F Br J Radiol; 2018 Jul; 91(1088):20180058. PubMed ID: 29750538 [TBL] [Abstract][Full Text] [Related]
15. Clinical benefit of 11C methionine PET imaging as a planning modality for radiosurgery of previously irradiated recurrent brain metastases. Momose T; Nariai T; Kawabe T; Inaji M; Tanaka Y; Watanabe S; Maehara T; Oda K; Ishii K; Ishiwata K; Yamamoto M Clin Nucl Med; 2014 Nov; 39(11):939-43. PubMed ID: 25140562 [TBL] [Abstract][Full Text] [Related]
16. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study. Orcurto V; Denys A; Voelter V; Schalenbourg A; Schnyder P; Zografos L; Leyvraz S; Delaloye AB; Prior JO Melanoma Res; 2012 Feb; 22(1):63-9. PubMed ID: 22027909 [TBL] [Abstract][Full Text] [Related]